Other languages Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.21 ^USD	-2.13%		+2.23%	-26.71%

Apr. 17	Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	CI
Apr. 15	Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bourse Zurich: en rouge pour finir la semaine "banques centrales"	Mar. 22
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22
Sector Update: Health Care	Mar. 22
Eton Pharmaceuticals Acquires U.S. Rights to PKU GOLIKE from Relief Therapeutics Holding SA	Mar. 22
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	Mar. 22
Relief Therapeutics trouve un partenaire de distribution US pour le Golike	Mar. 22
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	Mar. 22
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent	Feb. 21
Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	Feb. 21
Eton Pharmaceuticals Says Nitisinone Capsules Now Commercially Available in US	Feb. 02
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules	Feb. 02
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Eton Pharmaceuticals to Acquire Nitisinone Drug From Oakrum Pharma	23-10-04
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone	23-10-04
Top Premarket Gainers	23-08-11
Eton Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023	23-08-10
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Eton Pharmaceuticals, Inc. cancelled the acquisition of Certain assets including the Vistogard and Xuriden from Wellstat Therapeutics Corporation and Wellstat Biologics Corporation	23-06-29
Potential US Curbs on AI Chip Exports to China Drag Sentiment, Driving Premarket Losses for US Equity Futures	23-06-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Other languages

Filters